scPharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
scPharmaceuticals (Nasdaq: SCPH), a pharmaceutical company focused on revolutionizing cardiorenal healthcare through patient-centric innovations, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference.
John Tucker, President & Chief Executive Officer, will deliver a presentation on Wednesday, February 12 at 2:40PM ET. The presentation will be accessible via webcast through the company's website under the Investor Relations section's 'News & Events' tab.
scPharmaceuticals (Nasdaq: SCPH), un'azienda farmaceutica impegnata a rivoluzionare la salute cardiorenale attraverso innovazioni centrate sul paziente, ha annunciato la sua partecipazione alla 35ª Conferenza Annuale sulle Scienze della Salute di Oppenheimer.
John Tucker, Presidente e Amministratore Delegato, presenterà un intervento mercoledì 12 febbraio alle 14:40 ET. La presentazione sarà accessibile tramite webcast sul sito web dell'azienda nella sezione Relazioni con gli Investitori, sotto la scheda 'Notizie e Eventi'.
scPharmaceuticals (Nasdaq: SCPH), una compañía farmacéutica enfocada en revolucionar la atención cardiorenal a través de innovaciones centradas en el paciente, ha anunciado su participación en la 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer.
John Tucker, Presidente y Director Ejecutivo, realizará una presentación el miércoles 12 de febrero a las 2:40 PM ET. La presentación será accesible a través de transmisión web en el sitio web de la compañía en la sección de Relaciones con Inversores, bajo la pestaña 'Noticias y Eventos'.
scPharmaceuticals (Nasdaq: SCPH)은 환자 중심의 혁신을 통해 심장 및 신장 건강 관리를 혁신하는 데 주력하는 제약 회사로, 오펜하이머 제35회 연례 헬스케어 생명 과학 회의에 참여한다고 발표했습니다.
존 터커 CEO는 2월 12일 수요일 오후 2시 40분 ET에 발표를 할 예정입니다. 발표는 회사 웹사이트의 투자자 관계 섹션 '뉴스 및 이벤트' 탭을 통해 웹캐스트로 접속할 수 있습니다.
scPharmaceuticals (Nasdaq: SCPH), une entreprise pharmaceutique axée sur la révolution des soins de santé cardiorénaux grâce à des innovations centrées sur le patient, a annoncé sa participation à la 35e Conférence Annuelle sur les Sciences de la Santé d'Oppenheimer.
John Tucker, Président et Directeur Général, fera une présentation le mercredi 12 février à 14h40 ET. La présentation sera accessible via webcast sur le site de l'entreprise dans la section Relations Investisseurs sous l'onglet 'Actualités & Événements'.
scPharmaceuticals (Nasdaq: SCPH), ein pharmazeutisches Unternehmen, das sich auf die Revolutionierung der kardiorenalen Gesundheitsversorgung durch patientenzentrierte Innovationen konzentriert, hat seine Teilnahme an der 35. Jahreskonferenz für Gesundheitswissenschaften von Oppenheimer bekannt gegeben.
John Tucker, Präsident und CEO, wird am Mittwoch, den 12. Februar um 14:40 Uhr ET eine Präsentation halten. Die Präsentation wird über einen Webcast auf der Website des Unternehmens im Bereich Investor Relations unter dem Tab 'Nachrichten & Veranstaltungen' zugänglich sein.
- None.
- None.
BURLINGTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President & Chief Executive Officer, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12 at 2:40PM ET.
A webcast of the presentation can be accessed here or under “News & Events” in the Investor Relations section of the Company’s website, www.scPharmaceuticals.com.
About scPharmaceuticals
At scPharmaceuticals, we are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated treatments that address unmet patient needs.
Our goal is to become the foremost advocate for patient-centric cardiorenal care, driving global health improvements through specialized, multidisciplinary approaches. scPharmaceuticals is expanding its reach, offering integrated therapies and products that address diverse healthcare needs and potentially improve the lives of our patients. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.
Katherine Miranda
scPharmaceuticals Inc., 781-301-6869
kmiranda@scpharma.com
Investors:
Nick Colangelo
Gilmartin Group, 339-225-1047
Nick@GilmartinIR.com
FAQ
When is scPharmaceuticals (SCPH) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch scPharmaceuticals' (SCPH) Oppenheimer Conference presentation?
Who will represent SCPH at the Oppenheimer Healthcare Conference 2025?
Which annual healthcare conference is SCPH participating in February 2025?
